Cargando…
Evaluation of Sensitivity to Endocrine Therapy Index (SET2,3) for Response to Neoadjuvant Endocrine Therapy and Longer-Term Breast Cancer Patient Outcomes (Alliance Z1031)
PURPOSE: To evaluate prediction of response and event-free survival (EFS) following neoadjuvant endocrine therapy by SET2,3 index of nonproliferation gene expression related to estrogen and progesterone receptors adjusted for baseline prognosis. EXPERIMENTAL DESIGN: A correlative study was conducte...
Autores principales: | Suman, Vera J., Du, Lili, Hoskin, Tanya, Anurag, Meenakshi, Ma, Cynthia, Bedrosian, Isabelle, Hunt, Kelly K., Ellis, Matthew J., Symmans, W. Fraser |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9357183/ https://www.ncbi.nlm.nih.gov/pubmed/35653124 http://dx.doi.org/10.1158/1078-0432.CCR-22-0068 |
Ejemplares similares
-
Surgical Management of Axilla Following Neoadjuvant Endocrine Therapy
por: Murphy, Brenna M., et al.
Publicado: (2021) -
ASO Visual Abstract: Surgical Management of Axilla Following Neoadjuvant Endocrine Therapy
por: Murphy, Brenna M., et al.
Publicado: (2021) -
Steroid Ligands, the Forgotten Triggers of Nuclear Receptor Action; Implications for Acquired Resistance to Endocrine Therapy
por: Bleach, Rachel, et al.
Publicado: (2021) -
Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor–Positive (HR+)/HER2-Negative Metastatic Breast Cancer
por: Davis, Andrew A., et al.
Publicado: (2023) -
Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trial
por: Ellis, Matthew J., et al.
Publicado: (2008)